Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to…
Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022. Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a…
Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment…
Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology. Duisburg, Germany, and Lyon, France, 5 October 2021. Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat cancers with high unmet needs and Mablink Bioscience S.A.S. a biotechnology company developing…
Key Opinion Leaders bring many years of ADC development expertise to the company
Duisburg, Germany – Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).
Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr.…
Lead program is a Nectin-4-targeting ADC with potential across a range of hard to treat cancers Duisburg, Germany – Marseille, France, 22 November 2019: Emergence Therapeutics announced today that is has entered into a definitive financing agreement with a syndicate of leading European life science investors. In this Seed Round, founding investor Kurma Partners was…
Focus on best combination of validated targets and ADC technology to tackle hard to treat cancers Duisburg, Germany – Marseille, France, 1 October 2019: Emergence Therapeutics AG today announced its incorporation by founders Jack Elands, Xavier Preville and Kurma Partners. Emergence Therapeutics is a new pan-European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics…